ClinicalTrials.gg
RecruitingNCT06979323Updated Jul 2, 2026

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

A Phase 3 interventional study of Depemokimab in Asthma, sponsored by GlaxoSmithKline. Recruiting at 50 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2024, registered May 2025).
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.

Planned enrollment
6th of 10
150 · median 273
Started
2024
the only one that year
Phase 3
7 of 10
3 open now
Registered
8th of 10
by date
Lead sponsor
10 of 10
GlaxoSmithKline

Among the 10 studies testing depemokimab in Asthma, this one is the 6th largest by planned enrollment, is the only one that started in 2024, is one of 7 in phase 3, and was the 8th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About depemokimab

depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing depemokimab in Asthma, or all of them as a file.
02

Study summary

Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Depemokimab
  • Asthma
  • Type 2 Inflammation
  • Eosinophilic Phenotype
  • High Resolution Computed Tomography (HRCT)
  • Bronchoscopy
  • IMAGINE study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented clinical diagnosis of asthma for greater than or equal to (>=) 2 years as per the National Heart, Lung, and Blood Institute guidelines (NHLBI, 2020) or GINA guidelines (GINA, 2024), or joint guidance from the British Thoracic Society, National Institute for Health and Care Excellence, and Scottish Intercollegiate Guidelines Network [NICE, 2024] along with the following: an eosinophilic phenotype as evidenced by a blood eosinophil count of >=300 cells/microliters (mcL) at screening or a documented history of blood eosinophil count >=300 cells/mcL within 3 months prior to screening; Exhaled nitric oxide (FeNO) measure of >=25 parts per billion (ppb) recorded at screening; and a previously confirmed history of >= 2 exacerbations requiring treatment with systemic (SCS; intramuscular [IM], intravenous [IV], or oral), in the 12 months prior to screening, despite the use of medium to high dose Inhaled corticosteroids (ICS)
  • Uncontrolled asthma indicated by Astha Control Questionnaire-5 (ACQ-5) greater than (>) 1.5 recorded at screening
  • Persistent airflow obstruction as indicated by pre-bronchodilator Forced Expiration Volume in 1 second () less than (\<) 80 percentage (%) predicted (GLI 2012) and recorded at screening
  • A well-documented requirement for regular treatment with medium or high dose ICS (in the 12 months prior to screening with or without maintenance oral corticosteroids [OCS])
  • Current treatment with at least one additional asthma controller medication, besides ICS, for at least 3 months [for example, Long-acting Beta 2 agonists [LABA], Long-acting muscarinic antagonists [LAMA], leukotriene receptor antagonist (LTRA), or theophylline]
  • Male Participants: No additional requirements for male participants
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: is a participant of non- (PONCBP) or is a participant of childbearing potential (POCBP) and using a method that is highly effective (with a failure rate of \<1% per year), with low user dependency,
  • A POCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention
  • Capable of giving written ,
  • For the bronchoscopy sub study participants who sign the Informed Consent for the sub study, the following additional eligibility criteria will apply:

    • Participants not on maintenance OCS (oral corticosteroids) at the time of screening.
    • Participants with post bronchodilator FEV1 >= 50% predicted
    • Participants with no known increased risk for bleeding or clotting abnormalities including: No history of easy bleeding, bruising or known bleeding diathesis; No current anticoagulant and antiplatelet therapy; No acetylsalicylic acid use within 2 weeks of the planned procedure; Normal screening count
    • Participants with no specific to bronchoscopy with endobronchial biopsy in the opinion of the investigator
    • No history of allergic reaction to local anesthesia or general anesthetic agent, whichever is relevant to the procedure being performed

Exclusion criteria

Exclusion Criteria:

  • Presence of a known pre-existing, lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or a history of lung cancer. Participants with current diagnoses of emphysema or chronic bronchitis ( [COPD] other than asthma) are excluded
  • Participants with other conditions that could lead to elevated eosinophils such as hyper eosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly known as Churg-Strauss Syndrome) or eosinophilic esophagitis
  • Participants who developed an exacerbation within 4 weeks before screening
  • Participants with a known, pre-existing parasitic infestation within 6 months prior to screening unless treated and evidenced to have been resolved
  • A known immunodeficiency (e.g. HIV), other than that explained by the use of (CSs) taken as therapy for asthma
  • A current or previous history of cancer in remission for less than 12 months prior to screening
  • Participants who have known, pre-existing, clinically significant cardiac, endocrine, , metabolic, neurological, psychiatric, renal, gastrointestinal, hepatic, hematologic abnormalities or any other system abnormalities that are uncontrolled with standard treatment
  • Participants with current diagnosis of vasculitis
  • Participants who have a previous documented failure with anti-IL-5/5R therapy
  • Participants who have received monoclonal antibody (mAb) therapy targeting IL 5/5R, IL 4R/IL 13, IL 33, IgE, or Thymic Stromal Lymphpoietin (TSLP) within 12 months or 5 terminal phase half-lives of the drug, whichever is longer prior to the screening. Authorized treatments for Coronavirus disease-2019 (COVID-19) are permitted
  • Participants who have received treatment with an drug within the past 30 days or 5 terminal phase half-lives of the drug whichever is longer, prior to the first dose of study intervention (this also includes investigational formulations of marketed products)
  • Previously participated in any clinical study with biologic treatments for asthma (for example, omalizumab, mepolizumab, dupilumab, reslizumab, benralizumab, other mAbs (including Tezepelumab) or depemokimab and received study intervention (including placebo) within 12 months prior to the first dose of study intervention
  • A history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to the first dose of study intervention
  • Current smokers or former smokers with a smoking history >=20 pack years (number of pack years = [number of cigarettes per day/20] x number of years smoked) and vapers
  • Participants with allergy/intolerance to a mAb or biologic or any of the of depemokimab
  • Participants who are pregnant or breastfeeding
  • Participants who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations
  • Participants who have occupational ionizing-radiation exposure exceeding 10 Millisievert (mSV) over 3 years as documented with a dosimeter; have been exposed to elevated ionizing radiation from research imaging studies, for example, Participation in a research study with a single positron emission tomography scan in the past 3 years, and Participation in a research study with 2 or more computed tomography (CT) scans in the past 3 years in the following anatomical regions: chest, abdomen, cardiac, or spine
  • Presence of metal objects that may interfere with chest CT quantification including presence of a cardiac pacemaker, defibrillator, metal prosthetic heart valve, metal projectile or metal weapon fragment (bullet, shrapnel, shotgun shot) or metal shoulder prosthesis
  • Evidence of clinically significant abnormality in the hematological, biochemical or urinalysis screen at screening (Visit 0), as judged by the investigator
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Depemokimab

    Participants with asthma with type 2 inflammation will receive depemokimab.

    Biological: Depemokimab

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change from Baseline in Total Mucus Plug Volume Measured at Total Lung Capacity (TLC) at Week 26

    Mean change from baseline in total mucus plug volume measured at TLC at Week 26 will be assessed.

    Time frame: From Baseline up to Week 26

Secondary outcomes

  1. Mean Change from Baseline in Airway Wall Thickness Measured at TLC at Week 52

    Mean change from baseline in airway wall thickness measured at TLC at Week 52 will be assessed.

    Time frame: From Baseline up to Week 52

  2. Mean Change from Baseline in Airway Wall Thickness Measured at TLC at Week 26

    Mean change from baseline in airway wall thickness measured at TLC at Week 26 will be assessed.

    Time frame: From Baseline up to Week 26

  3. Mean Change from Baseline in Total Mucus Plug Volume Measured at TLC at Week 52

    Mean change from baseline in total mucus plug volume measured at TLC at Week 52 will be assessed.

    Time frame: From Baseline up to Week 52

  4. Mean Change from Baseline at Week 26 for Mucus Segment Score

    Mean change from baseline at Week 26 for mucus segment score will be assessed. The airway is divided into segments and each segment is given a score depending on the presence and severity of mucus. The segments are scored individually and then these scores are summed to give a total mucus score. (A mucus segment score between 0 - 4 indicates low levels of mucus production and a mucus segment score of 5 indicates higher levels of mucus production.)

    Time frame: From Baseline up to Week 26

  5. Mean Change from Baseline at Week 52 for Mucus Segment Score

    Mean change from baseline at Week 52 for mucus segment score will be assessed. The airway is divided into segments and each segment is given a score depending on the presence and severity of mucus. The segments are scored individually and then these scores are summed to give a total mucus score. (A mucus segment score between 0 - 4 indicates low levels of mucus production and a mucus segment score of 5 indicates higher levels of mucus production.)

    Time frame: From Baseline up to Week 52

  6. Mean Change from Baseline in Pre- and Post- Bronchodilator Forced Expiration Volume in 1 second (BD FEV1) at Week 26

    Mean change from baseline in Pre- and Post- BD FEV1 at Week 26 will be assessed.

    Time frame: From Baseline up to Week 26

  7. Mean Change from Baseline in Pre- and Post-BD FEV1 at Week 52

    Mean change from baseline in Pre- and Post-BD FEV1 at Week 52 will be assessed.

    Time frame: From Baseline up to Week 52

  8. Number of Participants with Adverse Events (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Week 65 (End of Study)

  9. Number of Participants with Serious Adverse Events (SAE)

    Any untoward medical occurrence resulting in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, possible drug-induced liver injury or any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent serious outcomes were categorized as SAE. Number of participants who had at least one SAE or non-SAE are presented.

    Time frame: Up to Week 65 (End of Study)

07

Study locations

49 of 50 sites recruiting
  • GSK Investigational Site
    Brooksville, Florida 34613, United States
    Recruiting
  • GSK Investigational Site
    Plantation, Florida 33324, United States
    Recruiting
  • GSK Investigational Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • GSK Investigational Site
    St Louis, Missouri 63110, United States
    Recruiting
  • GSK Investigational Site
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10029, United States
    Recruiting
  • GSK Investigational Site
    DuBois, Pennsylvania 15801, United States
    Recruiting
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140-5103, United States
    Recruiting
  • GSK Investigational Site
    McKinney, Texas 75069, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Mechelen, 2800, Belgium
    Recruiting
  • GSK Investigational Site
    Namur, 5101, Belgium
    Recruiting
  • GSK Investigational Site
    Ajax, Ontario L1S 2J5, Canada
    Recruiting
  • GSK Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
    Recruiting
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
    Recruiting
  • GSK Investigational Site
    Guangzhou, 510163, China
    Recruiting
  • GSK Investigational Site
    Shanghai, 200080, China
    Recruiting
  • GSK Investigational Site
    Tianjin, 300052, China
    Recruiting
  • GSK Investigational Site
    Brest, 29200, France
    Recruiting
  • GSK Investigational Site
    Créteil, 94010, France
    Recruiting
  • GSK Investigational Site
    La Tronche, 38700, France
    Recruiting
  • GSK Investigational Site
    Pessac, 33604, France
    Recruiting
  • GSK Investigational Site
    Reims, 51092, France
    Recruiting
  • GSK Investigational Site
    Bonn, 53127, Germany
    Recruiting
  • GSK Investigational Site
    Frankfurt, 60389, Germany
    Recruiting
  • GSK Investigational Site
    Athens, 106 76, Greece
    Recruiting
  • GSK Investigational Site
    Athens, 115 21, Greece
    Recruiting
  • GSK Investigational Site
    Heraklion, Greece
    Recruiting
  • GSK Investigational Site
    Ioannina, 45500, Greece
    Recruiting
  • GSK Investigational Site
    Thessaloniki, Greece
    Recruiting
  • GSK Investigational Site
    Catania, Italy
    Recruiting
  • GSK Investigational Site
    Genova, 16132, Italy
    Recruiting
  • GSK Investigational Site
    Roma, 00168, Italy
    Recruiting
  • GSK Investigational Site
    Rozzano, 20089, Italy
    Recruiting
  • GSK Investigational Site
    Jeonju, 54907, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 03080, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 03722, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 06351, South Korea
    Recruiting
  • GSK Investigational Site
    Barcelona, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, Spain
    Recruiting
  • GSK Investigational Site
    Benalmádena, 29631, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28031, Spain
    Recruiting
  • GSK Investigational Site
    Palma de Mallorca, 070120, Spain
    Recruiting
  • GSK Investigational Site
    Santander, 39008, Spain
    Recruiting
  • GSK Investigational Site
    Kaohsiung City, Taiwan
    Recruiting
  • GSK Investigational Site
    Taichung, 407, Taiwan
    Recruiting
  • GSK Investigational Site
    Taipei, 100, Taiwan
    Recruiting
  • GSK Investigational Site
    Bradford, BD9 6RJ, United Kingdom
    Recruiting
  • GSK Investigational Site
    London, SE1 9RT, United Kingdom
    Recruiting
  • GSK Investigational Site
    London, W6 8RF, United Kingdom
    Recruiting
  • GSK Investigational Site
    Southampton, SO16 6YD, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jan 2028, 41 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 41 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 18, 2025
StartActual
Jul 19, 2024
Primary completionEst.
Jan 5, 2028
CompletionEst.
Feb 11, 2028
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06979323
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 18, 2025
Start date
Jul 19, 2024
Primary completion
Jan 5, 2028 (estimated)
Completion
Feb 11, 2028 (estimated)
Last update
Jul 2, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion